DFG €66 million funding for 15 new research training groups
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
List view / Grid view
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
Lyme disease – an infection contracted from the bite of an infected tick– is an important emerging disease in the UK, and is increasing in incidence in people in the UK and large parts of Europe and North America.
New diagnoses for two types of skin cancer increased in recent years, according to a Mayo Clinic-led team of researchers.
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
SMi Group’s 3rd In Vitro Diagnostics conference will be take place on the 14th & 15th of June in London, bringing together global leading experts within the medical industry as they focus on the latest international trends within the field...
The collaboration focuses on the delivery of an educational programme consisting of a suite of flexible Master’s level professional courses including short ones and a full Master’s programme.
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has today announced the launch of the Chemical Safety Library (CSL) Service, which allows hazardous reaction information to be captured, stored and shared, to improve laboratory safety.
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
A research project, based out of the University of Liverpool, which will bring together a multidisciplinary team of cancer surgeons, medical oncologists and scientists in Liverpool, has been given the go ahead thanks to £200,000 worth of grant funding.